Harbour BioMed has concluded the first participant dosing in Phase I clinical trial of HBM7008, a bispecific antibody that acts on Tumor Associated Antigen B7H4x4-1BB, in Australia.

In this study, the company will evaluate HBM7008’s tolerability, safety, pharmacokinetics, pharmacodynamics, and initial anti-tumour activity in solid tumour patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Developed from the company’s HBICE platform, using the advantages of HBM HCAb and H2L2 platforms, HBM7008 targets B7H4, mediated crosslinking T cell activation through 4-1BB.

B7H4 is overexpressed on various solid tumours, including ovarian, breast, endometrial, and non-small cell lung cancers.

HBM7008 has crosslinking dependent specificity on tumours and potent immune modulation activity and demonstrated safety profile in pre-clinical study.

See Also:

Harbour BioMed said in a statement: “As the first-in-class bispecific antibody targeting B7H4 and 4-1BB, HBM7008 is expected to lead the development of next-generation immunotherapeutic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Following its global innovation and development strategy, Harbour BioMed will advance the global clinical development project of HBM7008 at full speed.”

Displaying high potency in the T cell co-stimulation and tumour growth inhibition, HBM7008 may also translate to better safety due to its TAA-mediated crosslinking T cell activation dependency.

Due to its unique specificity on tumours and immune modulation activity, the antibody is said to be a promising therapeutic in PD-L1 negative or PD-1/PD-L1 resistant patients.

Furthermore, it has the potential to avoid 4-1BB liver toxicity risk observed in other products.

Last month, Harbour BioMed announced an international out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody HBM7022.

In May last year, Harbour BioMed started dosing patients with HBM4003 in the second Phase I part of a Phase Ib/IIa trial for solid tumours.